ATM and cancer: However, in NKX3.1-expressing cancer cases, the expressional loss of NKX3.1 after androgen deprivation therapy also results in functional loss, leading to deregulated activation of antioxidant response (Debelec-Butuner et al., 2015) and ATM-mediated DDR mechanisms (Bowen et al., 2013).